MARTINSRIED, Germany and PARIS, France, September 21 /PRNewswire/ -- 4SC AG, a German drug discovery and development company and Mutabilis S.A., a French biotech company, focusing on the discovery of new therapeutic approaches for controlling nosocomial (hospital-acquired) infections, announced today the signing of a research partnership.
This partnership aims to identify new molecules as a basis for drug discovery against an undisclosed target provided by Mutabilis. 4SC will use its proprietary virtual High Throughput Screening technology 4Scan(R) to screen a database of 4.6 million small organic molecules in order to identify new active compounds, that bind to the specific target. Mutabilis will then receive a selection of best ranked molecules for biological testing and further evaluation. In return, 4SC receives undisclosed research funding and will be eligible for milestone payments.
"We are delighted that Mutabilis has chosen 4SC for this research partnership", commented Dr Ulrich Dauer, CEO of 4SC. "This deal is yet another validation of 4SC's technology platform. It confirms, once again, the growing acceptance of virtual High Throughput Screening for hit identification with the objective to develop novel lead compounds against important disease-related targets."
Mutabilis has validated new targets for anti-infective drugs and has built up an internal drug discovery strategy based on a medicinal chemistry platform, structural biology and rational approaches.
"For our drug discovery projects we focus on target information's and rational design. We are pleased to start this collaboration with 4SC, which, we believe, will give us a unique and fast capability of identifying lead compounds for our targets", said Alexis Denis, Head of Medicinal Chemistry and Sonia Escaich, CEO of Mutabilis
Mutabilis S.A., Paris, France, is a biopharmaceutical company specialising in antibacterial drug discovery. The company's focus is to create a new class of anti-infective drugs by developing molecules which bypass the various modes of action of today's antibiotics. This new therapeutic approach is based on targeting virulence determinants to inhibit pathogenic bacteria spreading into the host. The company aim is the prevention and treatment of severe infections caused by gram negative and gram positive bacteria.This new approach opens the way for new treatments in many areas, especially in the field of nosocomial infections.
Mutabilis S.A. is based in the Necker medical school in Paris, France. For more information on Mutabilis S.A.: http://www.mutabilis.fr/
4SC is a drug discovery and development company that uses its cheminformatics-based technological platform for the discovery and development of new drug candidates. By combining the disciplines of chemistry and biology with the proprietary virtual High Throughput Screening technology, 4SCan(R), the time and cost of advancing a drug candidate to the development phase can be significantly reduced. The company's therapeutic focus centres on hyperproliferative and infectious diseases. The drug candidate SC12267 for treatment of rheumatoid arthritis from 4SC's most advanced project is currently completing clinical Phase I. Additional research programs in the disease areas of cancer, inflammation and bacterial infections are currently in the discovery and preclinical evaluation stage. 4SC, which was founded in 1997, today employs 60 people and is based in Martinsried, near Munich, Germany.
For more information please contact:
4SC AG Mutabilis S.A.
Bettina von Klitzing Sonia Escaich
Am Klopferspitz 19a 156, rue de Vaugirard
D-82152 Martinsried 75015 Paris
Tel: +49-89-700-763-0 Tel: +33-140615330
eMail: Bettina.von.Klitzing@4sc.com eMail: firstname.lastname@example.org://www.4sc.de/http://www.mutabilis.fr/
CONTACT: For more information please contact: 4SC AG, Bettina vonKlitzing, Am Klopferspitz 19a, D-82152 Martinsried, Tel:+49-89-700-763-0, eMail: Bettina.von.Klitzing@4sc.com;Mutabilis S.A., Sonia Escaich, 156, rue de Vaugirard, 75015Paris, Tel: +33-140615330, eMail: email@example.com